Mikhail Eydelman - 30 Dec 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, Gen Counsel & Corp Sec
Signature
Mikhail Eydelman, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
30 Dec 2022
Transactions value $
$0
Form type
4
Filing time
04 Jan 2023, 15:31:46 UTC
Previous filing
09 Jun 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCVX Common Stock 8,032 30 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +27,500 $0.000000 27,500 30 Dec 2022 Common Stock 27,500 $47.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 532 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2022.
F2 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.